144 related articles for article (PubMed ID: 37918855)
21. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
22. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
[TBL] [Abstract][Full Text] [Related]
23. Recent advance of spleen tyrosine kinase in diseases and drugs.
Shao Y; Zhang S; Zhang Y; Liu Z
Int Immunopharmacol; 2021 Jan; 90():107168. PubMed ID: 33264719
[TBL] [Abstract][Full Text] [Related]
24. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
25. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
26. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
Pamuk ON; Tsokos GC
Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
[TBL] [Abstract][Full Text] [Related]
27. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
28. Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors.
Cervi G; D'Alessio R; Bindi S; Buffa L; Burocchi A; Canevari G; Modugno M; Motto I; Saturno G; Orsini P
Eur J Med Chem; 2024 Apr; 270():116375. PubMed ID: 38604095
[TBL] [Abstract][Full Text] [Related]
29. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
30. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
31. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
32. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.
Novikov FN; Panova MV; Titov IY; Stroylov VS; Stroganov OV; Chilov GG
Sci Rep; 2021 Nov; 11(1):23120. PubMed ID: 34848799
[TBL] [Abstract][Full Text] [Related]
35. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.
Cho S; Jang E; Yoon T; Hwang H; Youn J
Clin Exp Immunol; 2023 Mar; 211(1):31-45. PubMed ID: 36346114
[TBL] [Abstract][Full Text] [Related]
36. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
37. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
[TBL] [Abstract][Full Text] [Related]
39. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
40. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
